Safety

Duetact (pioglitazone HCl plus glimepiride) fixed-dose combination tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

March 2015

Summary View

CONTRAINDICATIONS

  • Reported hypersensitivity reactions with glimepiride include cutaneous eruptions with or without pruritus as well as more serious reactions (e.g., anaphylaxis, angioedema, Stevens-Johnsons Syndrome, dyspnea)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
  • There have been postmarketing reports of hypersensitivity reactions in patients treated with glimepiride, including serious reactions such as anaphylaxis, angioedema, and Stevens-Johnson syndrome. If a hypersensitivity reaction is suspected, promptly discontinue <insert drug name>, assess for other potential causes for the reaction, and institute alternative treatment for diabetes.

DRUG INTERACTIONS

  • Drugs Affecting Glucose Metabolism section edited

ADVERSE REACTIONS

Post-Marketing Experience

Glimepride

added the following bullet:

  • Thrombocytopenia (including severe cases with platelet count less than 10,000/µL) and thrombocytopenic purpura
     

 

November 2013

Summary View

USE IN SPECIFIC POPULATIONS

Pediatric Use
  • Duetact is not recommended for use in pediatric patients based on adverse effects observed in adults, including fluid retention and congestive heart failure, fractures, and urinary bladder tumor. 

 

December 2010

Summary View

PRECAUTIONS

General: Glimepiride
  • Hemolytic Anemia - Treatment of patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency with sulfonylurea agents can lead to hemolytic anemia. Because DUETACT contains glimepiride which belongs to the class of sulfonylurea agents, caution should be used in patients with G6PD deficiency and a non-sulfonylurea alternative should be considered. In postmarketing reports, hemolytic anemia has also been reported in patients who did not have known G6PD deficiency.

 

Page Last Updated: 04/15/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.